ESOPHAGEAL CANCER

This study tests a combination of two chemotherapy drugs and an immunotherapy drug given before surgery to people with advanced head and neck cancer that can be removed. The goal is to shrink or kill the cancer enough so that patients may not need radiation after surgery, which c…

This study tests three different chemotherapy combinations in 320 people with advanced esophageal or stomach cancer that has not been treated before. The goal is to find which combination works best to keep the cancer from growing while causing the least nerve damage. Participant…

This study compares a new esophageal stent (Luso-Cor) with standard stents and vacuum therapy for closing leaks that can happen after weight-loss or cancer surgery on the stomach or esophagus. About 180 adults who develop these leaks will be enrolled. The goal is to see which met…

This study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, called T cells, which are genetically modified in a lab to better recognize and attack cancer cells. The main goa…

This study tests a new approach for people with advanced esophageal cancer. Participants receive proton beam radiation along with chemotherapy drugs (carboplatin and paclitaxel) before surgery. The main goal is to find the safest radiation dose and monitor side effects. About 30 …

This study tests whether adding an experimental drug called LBL-007 to standard chemotherapy and immunotherapy can better shrink or control advanced esophageal cancer. About 118 adults with inoperable or spread esophageal squamous cell carcinoma will receive either the triple com…

This study involved 60 adults with advanced esophageal cancer who were scheduled for chemotherapy and surgery. Some received a feeding tube early, at the time of diagnosis, while others got it later during surgery. The goal was to see if early tube feeding helps prevent muscle lo…

This study tests whether a drug called INCMGA00012 (a PD-1 inhibitor) can help prevent esophageal cancer from returning after patients have completed chemoradiation. About 110 adults with locally advanced esophageal squamous cell carcinoma will be randomly assigned to receive the…

This early-phase study tests a new drug called AB598, alone or with other treatments, in about 40 people with advanced solid tumors like lung, bladder, or ovarian cancer. The main goal is to check if the drug is safe and tolerable. Participants must have measurable tumors and be …

This study tests a treatment called photodynamic therapy (PDT) for people whose superficial esophageal cancer has come back or remained after prior treatments. Patients receive a drug that makes cancer cells sensitive to light, then a laser is used to destroy them. The goal is to…

This early-phase study tests whether giving healthy donor natural killer (NK) cells along with two drugs (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach/esophageal, or blood cancers. The NK cells are meant to attack cance…

This study looks at whether adding a special balloon-based internal radiation treatment after standard chemoradiation can lower the chance of the tumor coming back in people with esophageal cancer who choose not to have surgery. About 18 adults aged 20-85 with stage I-III esophag…

This early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…

This early-phase study tests whether combining endoscopic tumor removal with low-dose radiation, chemotherapy, and immunotherapy is safe for patients with early-stage esophageal cancer who cannot or choose not to have surgery. The goal is to preserve the esophagus while controlli…

This phase 3 trial tests whether adding immunotherapy (sintilimab) plus chemotherapy before standard chemoradiotherapy helps people with inoperable esophageal cancer live longer. About 242 adults aged 18-75 with stage II-IVA esophageal squamous cell carcinoma will either receive …

This early-phase trial tests whether giving immunotherapy drugs (nivolumab or nivolumab/relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. The goal is to see if this approach can ch…

This study compares two types of radiation therapy—proton beam therapy and standard IMRT—both given with chemotherapy for esophageal cancer. The goal is to see if the newer proton therapy is safer and just as effective at controlling the cancer. About 147 adults with esophageal c…

This study tests a new drug called Q702 combined with pembrolizumab (an immunotherapy) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and shrinks tumors. About 120 parti…

This study is for people with HER2-positive esophageal or stomach cancer who have finished chemoradiation and surgery but still had some cancer cells left. It tests whether a year-long combination of two drugs, trastuzumab deruxtecan (Enhertu) and nivolumab, can safely prevent th…

This early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…

This early-phase trial tests a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes adults with advanced stomach, es…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma). The therapy takes a patient's own immune cells and genetically equips them to recognize and attack tumors that …

This early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to target and attack cancer cells while sparing healthy ones. The study will check if the drug is safe and what dose wor…

This early-phase study tests adding a freezing treatment (cryotherapy) before standard chemoradiation for people with advanced esophageal cancer. The goal is to find the safest number of freezing sessions and see if it helps the immune system fight the cancer. Fourteen adults wil…

This early-stage study tests a new drug called IMT-009 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. About 67 participants will receive the drug intravenously,…

This early-phase study tests a personalized cell therapy (ADP-A2M4CD8) for people with advanced cancers like lung, ovarian, or melanoma that have a specific marker called MAGE-A4. The treatment uses the patient's own immune cells, modified to better attack the cancer, and is give…

This study looks at whether a simple, swallowable device can help screen for esophageal cancer in rural areas without needing a traditional endoscopy. About 110 people with chronic heartburn and other risk factors will try the device at their local clinic. The goal is to see if p…

This study tests a new magnetic dye and detector to find cancer that has spread to nearby lymph nodes in people with stomach or esophagus cancer. About 60 adults who are scheduled for surgery will receive the dye, and doctors will check how well it works compared to standard meth…

This study looks at whether proton beam therapy, a precise form of radiation, causes fewer severe side effects than standard radiation for people with esophageal cancer. About 22 patients with stage II or III esophageal cancer will receive proton therapy, and researchers will tra…

This study looks at whether drinking cola can help relieve sudden food blockages in the esophagus within 24 hours for people with esophageal cancer. Fifty participants who have trouble swallowing due to their cancer will be randomly assigned to drink cola or receive standard care…

This study looks at whether an 8-week program of personalized nutrition, exercise, and mental support can help people with pancreatic or esophageal cancer get stronger before surgery. About 9 participants will try the program, and researchers will check if they can complete most …

This study looks at whether a special type of scan (PET/MRI) can predict how well esophageal cancer responds to chemotherapy and radiation given before surgery. Researchers will compare scan results with tissue samples after surgery to see if the scans can tell who is responding …

This study looks at whether a blood test can find leftover cancer cells after standard chemoradiotherapy for esophageal cancer. People with a positive test may get extra chemotherapy and immunotherapy to lower the risk of the cancer coming back. The study will enroll 65 adults wi…

This study collects leftover tissue, blood, and other body fluids from up to 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in future lab studies to learn more about what causes these cancers…

This study reviews medical records from 230 adults across 15 hospitals in 2 countries to understand how brain metastases from stomach and esophageal cancers are treated. The goal is to see which local treatments (like surgery or radiation) work best and how long patients live aft…

This study explores whether doing a PET scan during radiation therapy can help doctors adjust the treatment plan to improve outcomes for people with cervical, vulvar, esophageal, or anal cancer. About 90 adults will receive standard radiation plus an extra PET scan partway throug…